Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-04

AUTHORS

Katherine B. Peters, Eric S. Lipp, Elizabeth Miller, James E. Herndon, Frances McSherry, Annick Desjardins, David A. Reardon, Henry S. Friedman

ABSTRACT

Prognosis of recurrent glioblastoma (GBM) is poor with 6-month progression-free survival (PFS6) ranging from 9 to 48% depending on the treatment regimen and use of anti-angiogenic therapies. We sought to study vorinostat (VOR), a histone deacetylase inhibitor, in combination with bevacizumab (BEV) and daily metronomic temozolomide (TMZ) in a Phase I/II trial in recurrent high-grade gliomas (HGGs). This was a Phase I/II open-label, single-arm study in recurrent HGG patients. Phase I primary endpoint was to determine the maximum tolerated dose (MTD) of VOR with BEV and daily TMZ. Phase II primary endpoint was PFS6. Regimen was BEV 10 mg/kg iv every 2 weeks, TMZ 50 mg/m2 po daily, and VOR 200 or 400 mg po alternating 7 days on then 7 days off throughout a 28-day cycle. Phase I portion enrolled nine subjects with three receiving VOR 200 mg and 6 receiving VOR 400 mg. With no dose-limiting toxicities (DLTs) at 200 mg and one DLT (thrombocytopenia, Grade 3) at 400 mg, the MTD was 400 mg. Phase II portion enrolled 39 GBM subjects, and PFS6 was 53.8% (95% CI 37.2-67.9%). Of note, 14 subjects had received prior BEV and all had received prior 5-day TMZ. Combination therapy with VOR, BEV, and daily TMZ was well tolerated and safe. While PFS6 was not statistically improved beyond historical controls, it is important to note that this was a heavily pretreated GBM population and further consideration is warranted in a less pretreated group. More... »

PAGES

349-356

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11060-017-2724-1

DOI

http://dx.doi.org/10.1007/s11060-017-2724-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1099729099

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29264836


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bevacizumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glioma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Temozolomide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vorinostat", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Duke University", 
          "id": "https://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine, DUMC 3624, 27710, Durham, NC, USA", 
            "Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA", 
            "Department of Neurology, Duke University Medical Center, Durham, NC, USA", 
            "Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Peters", 
        "givenName": "Katherine B.", 
        "id": "sg:person.0744714665.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744714665.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University", 
          "id": "https://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lipp", 
        "givenName": "Eric S.", 
        "id": "sg:person.0673234667.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673234667.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University", 
          "id": "https://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miller", 
        "givenName": "Elizabeth", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University", 
          "id": "https://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, USA", 
            "Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Herndon", 
        "givenName": "James E.", 
        "id": "sg:person.01175371665.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01175371665.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University", 
          "id": "https://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McSherry", 
        "givenName": "Frances", 
        "id": "sg:person.01311620265.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311620265.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University", 
          "id": "https://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA", 
            "Department of Neurology, Duke University Medical Center, Durham, NC, USA", 
            "Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Desjardins", 
        "givenName": "Annick", 
        "id": "sg:person.0701277507.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701277507.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dana\u2013Farber Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.65499.37", 
          "name": [
            "Division of Hematology/Oncology, Department of Medicine, Dana Farber Cancer Institute, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reardon", 
        "givenName": "David A.", 
        "id": "sg:person.01334047606.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334047606.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University", 
          "id": "https://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA", 
            "Department of Pediatrics, Duke University Medical Center, Durham, NC, USA", 
            "Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Friedman", 
        "givenName": "Henry S.", 
        "id": "sg:person.01333344755.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333344755.48"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00280-009-0969-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002185616", 
          "https://doi.org/10.1007/s00280-009-0969-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-009-0969-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002185616", 
          "https://doi.org/10.1007/s00280-009-0969-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-009-0969-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002185616", 
          "https://doi.org/10.1007/s00280-009-0969-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-06-2309", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004441322"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-12-1841", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007788547"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.12.2440", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008387745"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6605412", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008522472", 
          "https://doi.org/10.1038/sj.bjc.6605412"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6605412", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008522472", 
          "https://doi.org/10.1038/sj.bjc.6605412"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-011-0749-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008786951", 
          "https://doi.org/10.1007/s11060-011-0749-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.26381", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013882923"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdp591", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019574105"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bcp.2007.03.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020515579"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.19.0694", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024184761"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-13-0708", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029146743"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1205108", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029964001", 
          "https://doi.org/10.1038/sj.onc.1205108"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1205108", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029964001", 
          "https://doi.org/10.1038/sj.onc.1205108"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-06-0914", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030937992"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-14-2737", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032845647"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/13543784.16.7.1111", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033068183"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-013-1317-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033289999", 
          "https://doi.org/10.1007/s11060-013-1317-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jcb.20045", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033705052"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-011-0722-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033962632", 
          "https://doi.org/10.1007/s11060-011-0722-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/neuonc/nos273", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037838897"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-07-0835", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037855860"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.surg.2005.06.016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039224903"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.surg.2005.06.016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039224903"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd2227", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041876399", 
          "https://doi.org/10.1038/nrd2227"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd2227", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041876399", 
          "https://doi.org/10.1038/nrd2227"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.19.8721", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042965400"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.26.3541", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043187529"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2005-09-008086", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043603884"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0142704", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043978262"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.2009-0121", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044143381"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/neuonc/nor187", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044853860"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cad.0b013e32834631e0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045090940"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cad.0b013e32834631e0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045090940"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1756-8722-2-31", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045484172", 
          "https://doi.org/10.1186/1756-8722-2-31"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-010-0127-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051066151", 
          "https://doi.org/10.1007/s11060-010-0127-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-010-0127-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051066151", 
          "https://doi.org/10.1007/s11060-010-0127-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa043330", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052112015"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/ijo.30.5.1181", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071516511"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/neuonc/noq099", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078202685"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078663594", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078713726", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-04", 
    "datePublishedReg": "2018-04-01", 
    "description": "Prognosis of recurrent glioblastoma (GBM) is poor with 6-month progression-free survival (PFS6) ranging from 9 to 48% depending on the treatment regimen and use of anti-angiogenic therapies. We sought to study vorinostat (VOR), a histone deacetylase inhibitor, in combination with bevacizumab (BEV) and daily metronomic temozolomide (TMZ) in a Phase I/II trial in recurrent high-grade gliomas (HGGs). This was a Phase I/II open-label, single-arm study in recurrent HGG patients. Phase I primary endpoint was to determine the maximum tolerated dose (MTD) of VOR with BEV and daily TMZ. Phase II primary endpoint was PFS6. Regimen was BEV 10\u00a0mg/kg iv every 2\u00a0weeks, TMZ 50\u00a0mg/m2 po daily, and VOR 200 or 400\u00a0mg po alternating 7\u00a0days on then 7\u00a0days off throughout a 28-day cycle. Phase I portion enrolled nine subjects with three receiving VOR 200\u00a0mg and 6 receiving VOR 400\u00a0mg. With no dose-limiting toxicities (DLTs) at 200\u00a0mg and one DLT (thrombocytopenia, Grade 3) at 400\u00a0mg, the MTD was 400\u00a0mg. Phase II portion enrolled 39 GBM subjects, and PFS6 was 53.8% (95% CI 37.2-67.9%). Of note, 14 subjects had received prior BEV and all had received prior 5-day TMZ. Combination therapy with VOR, BEV, and daily TMZ was well tolerated and safe. While PFS6 was not statistically improved beyond historical controls, it is important to note that this was a heavily pretreated GBM population and further consideration is warranted in a less pretreated group.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s11060-017-2724-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "137"
      }
    ], 
    "name": "Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas", 
    "pagination": "349-356", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "054c50846ca3b45827f2e8bd4e0ff9ba84cae1e28bfc87232c7748df13c7c49f"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29264836"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309335"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11060-017-2724-1"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1099729099"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11060-017-2724-1", 
      "https://app.dimensions.ai/details/publication/pub.1099729099"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:32", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000346_0000000346/records_99809_00000004.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs11060-017-2724-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11060-017-2724-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11060-017-2724-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11060-017-2724-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11060-017-2724-1'


 

This table displays all metadata directly associated to this object as RDF triples.

304 TRIPLES      21 PREDICATES      81 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11060-017-2724-1 schema:about N0c0e53c8c5e8484f96846b4347c37f56
2 N0d285189977b4ee8928eebc96a335dd4
3 N20dd3f464b31445f95d51cd07502d5a3
4 N253ef2e823af47dc9c96236e3ec49e25
5 N3a40607532d442bd9fba8157dc68dea0
6 N3b875272ee6945b3a4158a28b1c3d7e1
7 N3cfc58e0e13348059628910a59904ec7
8 N72673b1db3fe4cc9bcd1d6a8fc25a6d8
9 N9630d4832975434089417a915c8d3e13
10 N9e3e073a398a4241808362ef965c7db5
11 Nb93571297efc4bb393ddea4d699367a8
12 Nd81ad987a4e74c77b2e134b50d4a7cd2
13 Nd9cebf4555aa44ddb3f6b3923078f502
14 Ndc2e5ac863f74dcdb58ee41fea3cf947
15 Neab41d6df35f4102b21209addfd37309
16 Nfb25255452dd49a08475ac629d240f12
17 anzsrc-for:11
18 anzsrc-for:1103
19 schema:author Ne0466ffc2eaa4976a19177c675c8d4ad
20 schema:citation sg:pub.10.1007/s00280-009-0969-x
21 sg:pub.10.1007/s11060-010-0127-7
22 sg:pub.10.1007/s11060-011-0722-2
23 sg:pub.10.1007/s11060-011-0749-4
24 sg:pub.10.1007/s11060-013-1317-x
25 sg:pub.10.1038/nrd2227
26 sg:pub.10.1038/sj.bjc.6605412
27 sg:pub.10.1038/sj.onc.1205108
28 sg:pub.10.1186/1756-8722-2-31
29 https://app.dimensions.ai/details/publication/pub.1078663594
30 https://app.dimensions.ai/details/publication/pub.1078713726
31 https://doi.org/10.1002/cncr.26381
32 https://doi.org/10.1002/jcb.20045
33 https://doi.org/10.1016/j.bcp.2007.03.009
34 https://doi.org/10.1016/j.surg.2005.06.016
35 https://doi.org/10.1056/nejmoa043330
36 https://doi.org/10.1093/annonc/mdp591
37 https://doi.org/10.1093/neuonc/noq099
38 https://doi.org/10.1093/neuonc/nor187
39 https://doi.org/10.1093/neuonc/nos273
40 https://doi.org/10.1097/cad.0b013e32834631e0
41 https://doi.org/10.1158/1078-0432.ccr-06-0914
42 https://doi.org/10.1158/1078-0432.ccr-06-2309
43 https://doi.org/10.1158/1078-0432.ccr-07-0835
44 https://doi.org/10.1158/1078-0432.ccr-12-1841
45 https://doi.org/10.1158/1078-0432.ccr-13-0708
46 https://doi.org/10.1158/1078-0432.ccr-14-2737
47 https://doi.org/10.1182/blood-2005-09-008086
48 https://doi.org/10.1200/jco.2007.12.2440
49 https://doi.org/10.1200/jco.2008.19.0694
50 https://doi.org/10.1200/jco.2008.19.8721
51 https://doi.org/10.1200/jco.2009.26.3541
52 https://doi.org/10.1371/journal.pone.0142704
53 https://doi.org/10.1517/13543784.16.7.1111
54 https://doi.org/10.1634/theoncologist.2009-0121
55 https://doi.org/10.3892/ijo.30.5.1181
56 schema:datePublished 2018-04
57 schema:datePublishedReg 2018-04-01
58 schema:description Prognosis of recurrent glioblastoma (GBM) is poor with 6-month progression-free survival (PFS6) ranging from 9 to 48% depending on the treatment regimen and use of anti-angiogenic therapies. We sought to study vorinostat (VOR), a histone deacetylase inhibitor, in combination with bevacizumab (BEV) and daily metronomic temozolomide (TMZ) in a Phase I/II trial in recurrent high-grade gliomas (HGGs). This was a Phase I/II open-label, single-arm study in recurrent HGG patients. Phase I primary endpoint was to determine the maximum tolerated dose (MTD) of VOR with BEV and daily TMZ. Phase II primary endpoint was PFS6. Regimen was BEV 10 mg/kg iv every 2 weeks, TMZ 50 mg/m<sup>2</sup> po daily, and VOR 200 or 400 mg po alternating 7 days on then 7 days off throughout a 28-day cycle. Phase I portion enrolled nine subjects with three receiving VOR 200 mg and 6 receiving VOR 400 mg. With no dose-limiting toxicities (DLTs) at 200 mg and one DLT (thrombocytopenia, Grade 3) at 400 mg, the MTD was 400 mg. Phase II portion enrolled 39 GBM subjects, and PFS6 was 53.8% (95% CI 37.2-67.9%). Of note, 14 subjects had received prior BEV and all had received prior 5-day TMZ. Combination therapy with VOR, BEV, and daily TMZ was well tolerated and safe. While PFS6 was not statistically improved beyond historical controls, it is important to note that this was a heavily pretreated GBM population and further consideration is warranted in a less pretreated group.
59 schema:genre research_article
60 schema:inLanguage en
61 schema:isAccessibleForFree false
62 schema:isPartOf N679d18e3e5974a3eb529d43ca84754b4
63 Nb75c81ba8da3458cbe626758df4656c4
64 sg:journal.1094205
65 schema:name Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas
66 schema:pagination 349-356
67 schema:productId N3df8f48d9ea24675b3e67afd1a56003f
68 N593a33057e0346359cf23c7b30a53ef9
69 N600b4c280fbc415ea3f568da367b35ad
70 N793d607f6f1b4db289ef92e56670f859
71 N853ee08d40124710bf3b1c4dec3c2d88
72 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099729099
73 https://doi.org/10.1007/s11060-017-2724-1
74 schema:sdDatePublished 2019-04-11T09:32
75 schema:sdLicense https://scigraph.springernature.com/explorer/license/
76 schema:sdPublisher Nd91b87e65ffb4e86b3839ff397ee7f4e
77 schema:url https://link.springer.com/10.1007%2Fs11060-017-2724-1
78 sgo:license sg:explorer/license/
79 sgo:sdDataset articles
80 rdf:type schema:ScholarlyArticle
81 N0c0e53c8c5e8484f96846b4347c37f56 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Adult
83 rdf:type schema:DefinedTerm
84 N0d285189977b4ee8928eebc96a335dd4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Treatment Outcome
86 rdf:type schema:DefinedTerm
87 N20b2be7356d3470d89032b91f69a8015 rdf:first sg:person.0701277507.35
88 rdf:rest Nd401c6afa9504650a1c2021eadfb5707
89 N20dd3f464b31445f95d51cd07502d5a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Antineoplastic Combined Chemotherapy Protocols
91 rdf:type schema:DefinedTerm
92 N253ef2e823af47dc9c96236e3ec49e25 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Vorinostat
94 rdf:type schema:DefinedTerm
95 N3a40607532d442bd9fba8157dc68dea0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Neoplasm Recurrence, Local
97 rdf:type schema:DefinedTerm
98 N3b875272ee6945b3a4158a28b1c3d7e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Survival Analysis
100 rdf:type schema:DefinedTerm
101 N3cfc58e0e13348059628910a59904ec7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Antineoplastic Agents
103 rdf:type schema:DefinedTerm
104 N3df8f48d9ea24675b3e67afd1a56003f schema:name nlm_unique_id
105 schema:value 8309335
106 rdf:type schema:PropertyValue
107 N593a33057e0346359cf23c7b30a53ef9 schema:name pubmed_id
108 schema:value 29264836
109 rdf:type schema:PropertyValue
110 N600b4c280fbc415ea3f568da367b35ad schema:name doi
111 schema:value 10.1007/s11060-017-2724-1
112 rdf:type schema:PropertyValue
113 N679d18e3e5974a3eb529d43ca84754b4 schema:issueNumber 2
114 rdf:type schema:PublicationIssue
115 N72673b1db3fe4cc9bcd1d6a8fc25a6d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Bevacizumab
117 rdf:type schema:DefinedTerm
118 N793d607f6f1b4db289ef92e56670f859 schema:name readcube_id
119 schema:value 054c50846ca3b45827f2e8bd4e0ff9ba84cae1e28bfc87232c7748df13c7c49f
120 rdf:type schema:PropertyValue
121 N7bf5aa6b04054e768db59728f53459b4 rdf:first sg:person.01175371665.07
122 rdf:rest Na8bc040fbe994b6d81df5ef78c5589b0
123 N853ee08d40124710bf3b1c4dec3c2d88 schema:name dimensions_id
124 schema:value pub.1099729099
125 rdf:type schema:PropertyValue
126 N9630d4832975434089417a915c8d3e13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Dose-Response Relationship, Drug
128 rdf:type schema:DefinedTerm
129 N9e3e073a398a4241808362ef965c7db5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Glioma
131 rdf:type schema:DefinedTerm
132 Na489267a01ef4ad190ef1ea07662b14f rdf:first sg:person.0673234667.45
133 rdf:rest Nb27621163ae94f26b81d23cf3435c832
134 Na8bc040fbe994b6d81df5ef78c5589b0 rdf:first sg:person.01311620265.12
135 rdf:rest N20b2be7356d3470d89032b91f69a8015
136 Nb0db23f3b9cb4148affadc7f581f50c8 schema:affiliation https://www.grid.ac/institutes/grid.26009.3d
137 schema:familyName Miller
138 schema:givenName Elizabeth
139 rdf:type schema:Person
140 Nb27621163ae94f26b81d23cf3435c832 rdf:first Nb0db23f3b9cb4148affadc7f581f50c8
141 rdf:rest N7bf5aa6b04054e768db59728f53459b4
142 Nb75c81ba8da3458cbe626758df4656c4 schema:volumeNumber 137
143 rdf:type schema:PublicationVolume
144 Nb81dade070514ce7827c4344b37429c0 rdf:first sg:person.01333344755.48
145 rdf:rest rdf:nil
146 Nb93571297efc4bb393ddea4d699367a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Temozolomide
148 rdf:type schema:DefinedTerm
149 Nd401c6afa9504650a1c2021eadfb5707 rdf:first sg:person.01334047606.77
150 rdf:rest Nb81dade070514ce7827c4344b37429c0
151 Nd81ad987a4e74c77b2e134b50d4a7cd2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Middle Aged
153 rdf:type schema:DefinedTerm
154 Nd91b87e65ffb4e86b3839ff397ee7f4e schema:name Springer Nature - SN SciGraph project
155 rdf:type schema:Organization
156 Nd9cebf4555aa44ddb3f6b3923078f502 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Female
158 rdf:type schema:DefinedTerm
159 Ndc2e5ac863f74dcdb58ee41fea3cf947 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Brain Neoplasms
161 rdf:type schema:DefinedTerm
162 Ne0466ffc2eaa4976a19177c675c8d4ad rdf:first sg:person.0744714665.06
163 rdf:rest Na489267a01ef4ad190ef1ea07662b14f
164 Neab41d6df35f4102b21209addfd37309 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Humans
166 rdf:type schema:DefinedTerm
167 Nfb25255452dd49a08475ac629d240f12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Male
169 rdf:type schema:DefinedTerm
170 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
171 schema:name Medical and Health Sciences
172 rdf:type schema:DefinedTerm
173 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
174 schema:name Clinical Sciences
175 rdf:type schema:DefinedTerm
176 sg:journal.1094205 schema:issn 0167-594X
177 1573-7373
178 schema:name Journal of Neuro-Oncology
179 rdf:type schema:Periodical
180 sg:person.01175371665.07 schema:affiliation https://www.grid.ac/institutes/grid.26009.3d
181 schema:familyName Herndon
182 schema:givenName James E.
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01175371665.07
184 rdf:type schema:Person
185 sg:person.01311620265.12 schema:affiliation https://www.grid.ac/institutes/grid.26009.3d
186 schema:familyName McSherry
187 schema:givenName Frances
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311620265.12
189 rdf:type schema:Person
190 sg:person.01333344755.48 schema:affiliation https://www.grid.ac/institutes/grid.26009.3d
191 schema:familyName Friedman
192 schema:givenName Henry S.
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333344755.48
194 rdf:type schema:Person
195 sg:person.01334047606.77 schema:affiliation https://www.grid.ac/institutes/grid.65499.37
196 schema:familyName Reardon
197 schema:givenName David A.
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334047606.77
199 rdf:type schema:Person
200 sg:person.0673234667.45 schema:affiliation https://www.grid.ac/institutes/grid.26009.3d
201 schema:familyName Lipp
202 schema:givenName Eric S.
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673234667.45
204 rdf:type schema:Person
205 sg:person.0701277507.35 schema:affiliation https://www.grid.ac/institutes/grid.26009.3d
206 schema:familyName Desjardins
207 schema:givenName Annick
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701277507.35
209 rdf:type schema:Person
210 sg:person.0744714665.06 schema:affiliation https://www.grid.ac/institutes/grid.26009.3d
211 schema:familyName Peters
212 schema:givenName Katherine B.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744714665.06
214 rdf:type schema:Person
215 sg:pub.10.1007/s00280-009-0969-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1002185616
216 https://doi.org/10.1007/s00280-009-0969-x
217 rdf:type schema:CreativeWork
218 sg:pub.10.1007/s11060-010-0127-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051066151
219 https://doi.org/10.1007/s11060-010-0127-7
220 rdf:type schema:CreativeWork
221 sg:pub.10.1007/s11060-011-0722-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033962632
222 https://doi.org/10.1007/s11060-011-0722-2
223 rdf:type schema:CreativeWork
224 sg:pub.10.1007/s11060-011-0749-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008786951
225 https://doi.org/10.1007/s11060-011-0749-4
226 rdf:type schema:CreativeWork
227 sg:pub.10.1007/s11060-013-1317-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1033289999
228 https://doi.org/10.1007/s11060-013-1317-x
229 rdf:type schema:CreativeWork
230 sg:pub.10.1038/nrd2227 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041876399
231 https://doi.org/10.1038/nrd2227
232 rdf:type schema:CreativeWork
233 sg:pub.10.1038/sj.bjc.6605412 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008522472
234 https://doi.org/10.1038/sj.bjc.6605412
235 rdf:type schema:CreativeWork
236 sg:pub.10.1038/sj.onc.1205108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029964001
237 https://doi.org/10.1038/sj.onc.1205108
238 rdf:type schema:CreativeWork
239 sg:pub.10.1186/1756-8722-2-31 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045484172
240 https://doi.org/10.1186/1756-8722-2-31
241 rdf:type schema:CreativeWork
242 https://app.dimensions.ai/details/publication/pub.1078663594 schema:CreativeWork
243 https://app.dimensions.ai/details/publication/pub.1078713726 schema:CreativeWork
244 https://doi.org/10.1002/cncr.26381 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013882923
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1002/jcb.20045 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033705052
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1016/j.bcp.2007.03.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020515579
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1016/j.surg.2005.06.016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039224903
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1056/nejmoa043330 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052112015
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1093/annonc/mdp591 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019574105
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1093/neuonc/noq099 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078202685
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1093/neuonc/nor187 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044853860
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1093/neuonc/nos273 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037838897
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1097/cad.0b013e32834631e0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045090940
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1158/1078-0432.ccr-06-0914 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030937992
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1158/1078-0432.ccr-06-2309 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004441322
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1158/1078-0432.ccr-07-0835 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037855860
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1158/1078-0432.ccr-12-1841 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007788547
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1158/1078-0432.ccr-13-0708 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029146743
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1158/1078-0432.ccr-14-2737 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032845647
275 rdf:type schema:CreativeWork
276 https://doi.org/10.1182/blood-2005-09-008086 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043603884
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1200/jco.2007.12.2440 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008387745
279 rdf:type schema:CreativeWork
280 https://doi.org/10.1200/jco.2008.19.0694 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024184761
281 rdf:type schema:CreativeWork
282 https://doi.org/10.1200/jco.2008.19.8721 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042965400
283 rdf:type schema:CreativeWork
284 https://doi.org/10.1200/jco.2009.26.3541 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043187529
285 rdf:type schema:CreativeWork
286 https://doi.org/10.1371/journal.pone.0142704 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043978262
287 rdf:type schema:CreativeWork
288 https://doi.org/10.1517/13543784.16.7.1111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033068183
289 rdf:type schema:CreativeWork
290 https://doi.org/10.1634/theoncologist.2009-0121 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044143381
291 rdf:type schema:CreativeWork
292 https://doi.org/10.3892/ijo.30.5.1181 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071516511
293 rdf:type schema:CreativeWork
294 https://www.grid.ac/institutes/grid.26009.3d schema:alternateName Duke University
295 schema:name Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, USA
296 Department of Neurology, Duke University Medical Center, Durham, NC, USA
297 Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA
298 Department of Pediatrics, Duke University Medical Center, Durham, NC, USA
299 Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA
300 Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine, DUMC 3624, 27710, Durham, NC, USA
301 rdf:type schema:Organization
302 https://www.grid.ac/institutes/grid.65499.37 schema:alternateName Dana–Farber Cancer Institute
303 schema:name Division of Hematology/Oncology, Department of Medicine, Dana Farber Cancer Institute, Boston, MA, USA
304 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...